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Abstract. Despite mounting evidence that oncolytic viruses can be effective in treating cancer,
understanding the details of the interactions between tumour cells, oncolytic viruses and immune
cells that could lead to tumour control or tumour escape is still an open problem. Mathematical
modelling of cancer oncolytic therapies has been used to investigate the biological mechanisms
behind the observed temporal patterns of tumour growth. However, many models exhibit very
complex dynamics, which renders them difficult to investigate. In this case, bifurcation diagrams
could enable the visualisation of model dynamics by identifying (in the parameter space) the
particular transition points between different behaviours. Here, we describe and investigate two
simple mathematical models for oncolytic virus cancer therapy, with constant and immunity-
dependent carrying capacity. While both models can exhibit complex dynamics, namely fixed
points, periodic orbits and chaotic behaviours, only the model with immunity-dependent carry-
ing capacity can exhibit them for biologically realistic situations, i.e., before the tumour grows
too large and the experiment is terminated. Moreover, with the help of the bifurcation diagrams
we uncover two unexpected behaviours in virus-tumour dynamics: (i) for short virus half-life,
the tumour size seems to be too small to be detected, while for long virus half-life the tumour
grows to larger sizes that can be detected; (ii) some model parameters have opposite effects on
the transient and asymptotic dynamics of the tumour.
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1. Introduction
Despite recent advances in molecular pathology, virology and genetics, permanent cancer elimination or
even prolonged control of cancer are still elusive goals [8,39,48,52,53]. While there are experimental and
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clinical situations where cancers seem to be eliminated and patients cured [54], the majority of treatments
only delay cancer recurrence [52].
Mathematical models can be used to understand and design new experiments, by formulating hy-
potheses regarding the potential biological mechanisms that could lead to delayed cancer relapse or to
permanent elimination [8]. In fact, the last 10–20 years have seen an explosion in the number of determin-
istic mathematical models (both ODEs and PDEs) used to reproduce and further investigate different
cancer therapies (see [2, 25] and references therein). Here, we will focus on ODE models, since they pro-
vide a simpler framework within which to explore the interactions among the different components of the
tumour microenvironment [25]. In the context of these ODE models, we note that many simple models
incorporate nonlinear terms that account for the spatial architecture of solid tumours [25]. Usually the
first step (and sometimes the only step) in the analysis of such nonlinear mathematical models is to in-
vestigate the linear stability of steady states, with the purpose of identifying the mechanisms that ensure
a stable tumour-free steady state. Biologically, this stability means that the tumour can be permanently
eliminated, if it becomes sufficiently small. This approach is useful if the mathematical model has locally
stable tumour-free steady states. However, many models of cancer immunotherapies display only unstable
tumour-free steady states [13,14,34,47].
The existence of unstable steady states can give rise to chaotic dynamics. For the past twenty years,
chaotic behaviour has been proposed as a theoretical explanation for the unpredictability of cancer dy-
namics [18, 32, 38, 42, 43, 50, 55]. The presence of chaos, which causes the system to be unpredictable in
the long term, also implies that the dynamics can be altered by small parameter variations [6]. Therefore,
mathematical models for cancer growth that show chaotic behaviour might be useful for understanding
the dynamics of the biological system and for proposing new biological mechanisms to control cancer [38].
In this article we focus on cancer immune and oncolytic virotherapies (i.e., therapies based on oncolytic
viruses that replicate inside and destroy the cancer cells), which have expanded rapidly over the past
decade and entered clinical trials [49]. The goal of this study is to show that the nonlinear interactions
among the various components of the tumour microenvironment (e.g., immune cells, tumour cells, on-
colytic virus particles) can induce surprising bifurcations, including bifurcations to chaotic dynamics.
Understanding these transitions can help us better understand the type of models we use to describe
the biological problem, and the appropriateness of these models. To our knowledge, chaotic dynamics
has never previously been investigated in models for cancer-immune-virus interactions. Generally, these
models focus on the analytical investigation of the steady states and their stability, and on the numerical
investigation of the tumour and virus growth and spread patterns, with many studies also comparing
the simulation results with available experimental data [3, 7, 22, 33, 51, 58, 61–64, 66]. By focusing on the
chaotic aspects of models for tumour-immune-virus interactions, we aim to emphasise the complexity of
the dynamics produced by these types of systems, which might explain the current unsuccessful oncolytic
therapies. Moreover, we aim to show that some parameters that can be controlled experimentally can
have opposite effects on the transient and asymptotic dynamics of the model (i.e., could lead to a de-
crease in tumour size during the transient dynamics and an increase in tumour size during the asymptotic
dynamics).
To this end, we introduce a simple mathematical model that describes the interactions among cancer
cells, immune cells and oncolytic viruses (i.e., viruses that selectively infect and replicate inside cancer
cells). This model (which is a simplification of the model introduced in [27]) is based on a particular
experimental protocol derived in [10] to investigate the combined anti-tumour effect of vaccination and
oncolytic virotherapy. However, our model is sufficiently general to be applied to other combinations of
cancer therapies. We show that this model can exhibit complex dynamics such as limit cycles and chaotic
behaviour. Since these behaviours occur only after the tumour reaches its maximum size - as defined
by the carrying capacity - we modify the model to introduce density-dependent carrying capacity (with
the magnitude of the immune response influencing the tumour carrying capacity). The new model can
exhibit similarly complex dynamics but in slightly different parameter ranges. Since some of the model
parameters are free (i.e., could not be identified from available data or from the literature), we also create
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bifurcation diagrams to visualise model dynamics when we vary these free parameters. With the help of
these diagrams, we show that the chaotic dynamics exhibited by the two models would not necessarily be
detected in experimental settings, since the amplitudes of chaotic oscillations are too low for detection.
Moreover, we show that while some parameters have similar effects on the transient and asymptotic
behaviour of the tumour (i.e., changes in the parameters lead to tumour reduction for both transient and
asymptotic dynamics), other parameters can have opposite effects, by leading to a decrease in tumour
size during transient dynamics, and an increase in tumour size for asymptotic dynamics.
We begin in Section 2 by describing the nonlinear ODE model for tumour-immune-virus dynamics. In
Section 3, we discuss briefly the steady states and their linear stability, and then investigate numerically
the model’s transient and asymptotic dynamics indicating how chaos occurs for certain parameter ranges.
In Section 4 we introduce a density-dependent carrying capacity for tumour growth, which depends on
the level of tumour-infiltrating immune cells, and show that this new model can display experimentally-
undetectable chaotic behaviour. In Section 5 we investigate the dynamics of the model as we vary the
free parameters. We conclude in Section 6 with a discussion of the results.
2. Model description
The mathematical model we use to investigate the chaotic tumour-immune-virus dynamics follows an
experimental protocol derived in [10]. The protocol (depicted graphically in Fig.1(a)) involves two viruses,
a vaccine virus and an oncolytic virus, which carry the same tumour antigen and are administered
consecutively into tumour-bearing mice. (The tumour cells – melanoma cells in [10] – are injected into
mice a few days before treatment begins.) Generally, the first virus (the vaccine, Adenovirus in [10])
induces an immune response against the tumour antigens. The second virus (the oncolytic virus, Vesicular
Stomatitis Virus in [10]), which is usually administered after the first immune response wanes, induces
a much stronger anti-tumour immune response that could theoretically eliminate tumours. However, it
was shown in [10] that the Vesicular Stomatitis Virus (VSV) eliminated tumours only in some mice.
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Figure 1. (a) Timeline for the dual-immunization protocol developed in [10], and for our mathematical
model; (b) Graphical description of model (2.1). Once injected into the system, the virus particles will
affect the tumour cells as well as the memory immune cells that become activated and differentiate into
effector immune cells.
This immunisation protocol was first modelled and studied mathematically in [27], where the authors
considered two compartments (lymphoid tissue – where the immune memory cells are located, and the
peripheral tissue – where the tumour is located) to model the detailed interactions among tumour cells,
viruses, and immune cells. Despite the complexity of that model (described by seven equations), the
authors were able to detect and investigate a multi-instability phenomena where all steady states were
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unstable. However, because of the large parameter space, the authors did not engage in a systematics
search for chaos, and chaos was not detected for the parameter values investigated in [27].
Here, we introduce a simplified one-compartment model (see Figure 1(b)), which focuses only on the
oncolytic virus, and considers a memory response induced by the injection of this virus following the
vaccine virus. The state variables in this model are: the densities of infected (xi) and uninfected (xu)
tumour cells, the densities of two types of immune cells: effector cells (ye, cells that kill tumour cells) and
memory cells (ym, cells that proliferate in the presence of viral or tumour antigens), and the density of
oncolytic virus particles (v). The model is described by the following equations:
dxu(t)
dt
= rxu
(
1− xu + xi
K
)− dv xuv
hu + xu
− dx xuye
he + ye
, (2.1a)
dxi(t)
dt
= dv
xuv
hu + xu
− δxi − dx xiye
he + ye
, (2.1b)
dym(t)
dt
= pm
vym
hv + v
(
1− ym
M
)
, (2.1c)
dye(t)
dt
= pe
vym
hv + v
− deye − dtxuye, (2.1d)
dv(t)
dt
= δbxi − ωv. (2.1e)
Briefly, we assume that uninfected tumour cells grow logistically at intrinsic rate r (and have a carrying
capacity K). This assumption approximates the natural deceleration in the growth as the size of the
tumour increases [56]. The uninfected tumour cells can be infected with oncolytic viruses at rate dv, and
eliminated by the immune effector cells at rate dx. The infected tumour cells have a mean lifetime of 1/δ
(determined by the timescale of virus replication within these cells), and are eliminated by the immune
effector cells at rate dx. In the presence of the oncolytic virus, memory cells proliferate logistically at rate
pm and with a carrying capacity M . (This logistic term models competition for space among memory cells
[1].) At the time of proliferation, some memory cells differentiate into effector cells at rate pe. Effector cells
die at rate de, and are inactivated by tumour cells at rate dt. Finally, the oncolytic virus v is produced at
rate δ by the infected tumour cells (on average, each infected cell produces b virus particles), and has a
mean lifetime of 1/ω. To keep the model as simple as possible, we assume that the death rate of memory
cells is insignificant compared to their proliferation rate (i.e., equation (2.1c) does not include a decay
term). This assumption is realistic, since memory cells are long-lived cells, capable of persisting in the
host even in the absence of antigen. In contrast, most effector cells die during the contraction phase of
the immune response [60]. A graphical description of this model is presented in Fig.1(b).
To account for the spatial structure of solid tumours, which may hinder the spread of viral particles or
immune cells throughout the tumour [5, 9], the terms describing the interactions among virus particles,
immune cells, and tumour cells are chosen to be of Michaelis-Menten type [44]. These terms can also
account for the heterogeneity of the tumour microenevironment, which might lead, for example, to reduced
encounter rates between immune cells and infected tumour cells. We acknowledge here that the form of
these interaction terms are just an example of possible interaction functions, other studies considering for
example bi-linear interactions [62]. Therefore, the results presented here are particular to model (2.1).
3. Model analysis
3.1. Stability analysis
To understand the dynamics of model (2.1), we start by briefly discussing the linear stability of the steady
states. Model (2.1) has four types of steady states:
(i) a tumour-free (TF) steady state: (xu, xi, ym, ye, v) = (0, 0, y
∗
m, 0, 0), with y
∗
m∈R+;
(ii) a tumour-only (TO) steady state: (xu, xi, ym, ye, v) = (x
∗
u, 0, y
∗
m, 0, 0), with x
∗
u=K and y
∗
m∈R+;
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(iii) a tumour with virus but no immune response (TV) steady state: (xu, xi, ym, ye, v) = (x
∗
u, x
∗
i , 0, 0, v
∗),
with x∗u=
ωhu
dvb−ω , v
∗ = r(1−x
∗
u/K)
dv/(hu+x∗u)+rω/(δbK)
, x∗i =
ωv∗
δb ;
(iv) a steady state with all cell types and virus particles present (TVI): (xu, xi, ym, ye, v) =
(x∗u, x
∗
i , y
∗
m, y
∗
e , v
∗), with y∗m = M .
We observe that the steady-state memory population y∗m in the TF, TO and TVI states does not depend
on model parameters associated with either the virus, tumour or effector cell populations (y∗m = M
or y∗m = c, with c ∈ R+ some constant). This makes sense biologically, since (a) there is a steady-
state memory population following the first inoculation of the vaccine virus (see the vaccination protocol
described in Figure 1(a)); (b) even if the tumour population becomes eliminated, the memory population
continues to persist; (c) the memory population is long-lasting (in mice these cells can persist for years).
Of the four types of steady states, the TF and TV states are always locally unstable (see the discussion
in Appendix B). In particular, the TF state is always a saddle point. The stability of the TO state is
determined by the effective reproductive number (for the virus) associated with this state:
Re = dvb
ω
x∗u
hu + x∗u
. (3.1)
In particular, the TO state is stable when Re < 1 and unstable when Re > 1. For the parameter values
used in this paper (and described in Table 2), Re = 1 at ω ≈ 2.59, which corresponds to a virus mean
half-life of about 6.4 hours. Throughout this study, we restrict our investigation to values of ω < 2.59
(i.e, virus half-life greater than 6.4 hours) for which the TO state is always unstable since Re > 1. In
regard to the fourth steady state TVI, for the parameter values considered in this article, there is only
one type of TVI state, which is stable for ω ≥ 1.32/day and unstable for ω < 1.32/day. The stability of
the TF, TO and TV states can be established analytically, while the stability of the TVI state can be
established numerically, as discussed in [27] and here in Appendix B.
3.2. Transient and asymptotic behaviour of the system
Next, we investigate both the transient (t < 200−500 days) and asymptotic (t > 1000 days) dynamics of
model (2.1), as we vary parameter ω, which describes the elimination rate of virus particles. We focus on
this particular parameter since it can be manipulated experimentally: either by blocking viral clearance by
the reticulo-endothelial cells in the liver [11], or by prolonging the extracellular half-life of VSV particles
(from 3.5-8 hrs to almost double these values) through genetical manipulation of the virus [31].
In Figure 2 we show the transient behaviour of the tumour cells (panel (a)), virus particles (panel (b)),
memory cells (panel (c)) and effector cells (panel (d)), for ω = 1.38, corresponding to a virus half-life of
t1/2 = ln(2)/ω ≈ 12hr. We remark that tumour re-growth triggers an increase in the virus particles that
replicate inside tumour cells, and an increase in the effector cell population. The level of effector cells is
not high enough to eliminate the tumour cells - it can only reduce their level. However, this reduction in
tumour size occurs only after the tumour reached its carrying capacity on day 80, and thus it is irrelevant
from a treatment point of view (since the mice would be sacrificed by then [46]). Note that changes in
the initial data (see Table 1) might impact the transient dynamics of the system, by leading to a delay
or a faster increase in tumour growth.
One disadvantage of the use of VSV for clinical applications is its fast inactivation and elimination
[9,31]. Thus recent experimental studies focused on different methods to increase the half-life of the virus
[17, 31]. In Figure 3 we investigate the transient dynamics of the tumour cells (and the immune cells in
the inset) as we decrease ω from 1.39 to 1.0, corresponding to an increase in virus half-life up to ≈ 16.6hr.
Note that, for all ω values, the tumour can be reduced to very low densities but not eliminated completely.
Moreover, the reduction in ω leads to a delay in tumour relapse (e.g., for up to 150 days for ω = 1.0).
In regard to the asymptotic dynamics of system (2.1), we have seen in Figure 2(a) that the tumour
can approach a fixed point (e.g., when ω = 1.38). In Figure 4 we show two more types of asymptotic
dynamics obtained as we decrease ω: (a),(d) periodic orbits; (b),(c) chaotic-type behaviours. In fact, as
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Figure 2. An example of the transient dynamics of system (2.1) with the elimination rate of the
oncolytic virus ω = 1.38. We show (a) the tumour size, (b) the memory cell population, (c) the effector
cell population, (d) the viral load. Here, the solution seems to approach the TVI state (with y∗m = M
and x∗u, x∗i , y
∗
e , v
∗ > 0). See Tables 1 and 2 for initial conditions and parameter values.
ω is decreased from ω = 1.38/day to ω = 0.84/day, the system undergoes a series of bifurcations from
a steady-state (as in Figure 2(a), for ω = 1.38/day) to periodic orbits (Figure 4(a), for ω = 1.29/day),
followed by inverse period-doubling bifurcations which then lead to chaotic fluctuations (Figures 4(b),(c),
for ω = 1.26/day or ω = 1.15/day). As ω is decreased even further, the chaotic attractor collides with an
unstable orbit, which causes the system to move to a periodic orbit (Figure 4(d); ω = 1.1/day).
A clearer representation of this series of bifurcations is displayed in Figure 5. Panel (a) shows the
local maximum values of xu(t), for simulations ran for t ∈ [3000, 7000] days, and for ω ∈ [1.1, 1.29]
- corresponding to the dynamics presented in Figure 4. We observe period doubling bifurcations for
ω ∈ (1.267, 1.28), and a potential chaotic attractor for ω ∈ (1.19, 1.26) and again for ω ∈ (1.142, 1.167).
In the inset, we show the first return map to a Poincare´ section of the chaotic attractor built from the
local maxima of tumour size, for the chaotic attractor at ω = 1.26, constructed by plotting one tumour
maximum against the previous maximum: max(xu;n) vs. max(xu;n− 1); see [41]. In panel (b) we use the
algorithm in [65] to calculate the largest Lyapunov exponent (LE) for each ω ∈ [1.1, 1.29], and confirm
the existence of two regions of chaotic-like dynamics. We choose to plot the LE as it emphasises the
parameter regions where we have chaos. To understand what happens in these two chaotic regions, we
graph in panels (c), (d) and (e) the solution xu for ω near 1.145 (panel (c)), ω near 1.2476 (panel (d)) and
ω near 1.27 (panel (e)), where we know that chaotic-like behaviour occurs. Thus, as we slightly increase
ω above ω = 1.145 in panel (c), we obtain sequences of limit cycles of increasing periods (e.g., a period-5
cycle for ω = 1.145, a period-6 cycle for ω = 1.1461, and a period-7 cycle for ω = 1.1462). Note that
these limit cycles, are interspersed with chaotic dynamics - not shown here. In panel (d) we observe that
for ω = 1.24766, the trajectory visits the neighborhood of an unstable periodic orbit (during a so-called
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Figure 3. The transient tumour dynamics of system (2.1) as the elimination rate of the oncolytic
virus, ω, is decreased from ω = 1.39/day to ω = 1.0/day. The inset figures show the dynamics of the
effector immune cells. The continuous and dashed lines show the dynamics of the tumour and immune
cells for two different values of ω (in panel (b), the dynamics are quite similar, and the lines are hard to
distinguish). See Tables 1 and 2 for initial conditions and parameter values.
laminar phase) which is interrupted by a chaotic burst (at t ≈ 3550), a behaviour which is typical for
intermittencies, another route to chaos. Finally, in Figure 5(e) we show period-1 and a period-2 limit
cycles, part of the period-doubling route to chaos observed in panel (a) for ω ≈ 1.28.
To summarise, we note that small changes in the decay rate ω may have little effect on the transient
dynamics, but lead to different asymptotic dynamics. We need to emphasise that these conclusions depend
on the initial conditions used for simulations (and described in Table 1). Also, the chaotic behaviour
displayed by this ODE model is the results of various pathways to chaos: (i) the period-doubling route
for ω ∈ (1.19, 1.27); (ii) the route to chaos via intermittency observed, for example, for ω ≈ 1.24766.
4. Immunity-dependent carrying capacity
The complex dynamics discussed in the previous section occurs after the tumour visits the neighbourhood
of the TO steady state (i.e., the tumour carrying capacity), and thus is irrelevant from a treatment point
of view (since in an experimental setting the mice would be euthanised when tumour becomes very large
[46]). Next, we investigate the occurrence of chaotic dynamics when the tumour does not grow to such a
large size.
The presence of immune cells inside the tumour micro-environment has been associated with good
cancer prognosis [24,29]. In particular, the presence of tumour-infiltrating immune cells has been associ-
ated with a smaller tumour size and a lower tumour stage [24]. Therefore it is reasonable to assume that
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Figure 4. Examples of asymptotic tumour dynamics of system (2.1) for: (a) ω = 1.29, (b) ω = 1.26,
(c) ω = 1.15, (d) ω = 1.1. See Tables 1 and 2 for initial conditions and parameter values. The inset
figures show the projection of model dynamics onto the xu− ye plane, for time t ∈ (500, 2500) days. For
a more detailed depiction of the chaotic attractor obtained when ω = 1.26, see Appendix C.
these immune cells could also impede the tumour to grow towards its carrying capacity (by secreting
anti-angiogenic cytokines and promoting a tumour-hostile microenvironment [45]). Next we consider a
slightly modified version of equation (2.1a), where the tumour carrying capacity is limited by the size of
the immune response:
dxu(t)
dt
= rxu
(
1− xu + xi
K − cy
)
− dv xuv
hu + xu
− dx xuye
he + ye
. (4.1)
Here, cy is a correction term to account for the fact that the tumour microenvironment will not support
tumour growth towards its full carrying capacity. The variable y can be taken to be either or both immune
populations, i.e., y = ym, y = ye or y = ym+ye. The non-dimensional parameter c provides an indication
of how “tumour hostile” the microenvironment is.
The density-dependent carrying capacity we consider here is different from the terms in [30, 37, 59],
where the authors introduced separate equations for the evolution of tumour carrying capacity in response
to pro-angiogenic signals produced by both immune and cancer cells, or in response to various pro-
angiogenic and anti-angiogenic factors.
Next, we discuss not only the asymptotic dynamics of model (2.1)-(4.1) with density-dependent carry-
ing capacity, but also its transient dynamics since: (i) this transient regime is important in experimental
and clinical settings (which show variations in tumour growth patterns that are linked to variations in
the immune response - still difficult to understand due to the fact that initial conditions are not fully
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Figure 5. (a) Maximum values of uninfected tumour cells xu, for time t ∈ (3000, 7000). For periodic
solutions, this maximum is always the same. For chaotic solutions, the maximum values are very irregular.
The inset shows the first-return map for the chaotic attractor at ω = 1.26; (b) Largest Lyapunov
exponent, for ω ∈ (1.1, 1.29); (c) Density xu for ω = 1.145, ω = 1.1461 and ω = 1.1462; (d) Density xu
for ω = 1.24766; Note the irregular burst at t ≈ 3550; (e) Density xu for ω = 1.278 and ω = 1.28. See
Tables 1 and 2 for initial conditions and parameter values.
known/controlled in these settings [35]), and (ii) to emphasise the difference in the transient and asymp-
totic dynamics of the system.
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Figure 6. Density of uninfected tumour cells xu for different values of ω, c, and different choices
of y variable. The dashed horizontal like shows the value of the carrying capacity K. The inset shows
the transient tumour dynamics (i.e., t < 200). (a) ω = 1.26, c = 1000 and y = ye + ym. (b) ω = 1.26,
c = 1000, y = ym. (c) ω = 1.26, c = 17000, y = ym. (d) ω = 1.15, c = 17000, y = ym. All other
parameters are as in Table 2. Note that ym(t) + ye(t) < K/c in all these simulations (not shown here).
Figure 6 shows the asymptotic and transient (in the inset) tumour dynamics for model (2.1b)-(2.1e) &
(4.1), for particular values of ω, c and two choices of y-variable. In panels (a)-(b) we compare the choice of
y variable (y = ym or y = ym + ye) on the tumour growth pattern, and notice that both y = ym + ye and
y = ym lead to similar outcomes (and in all cases max(y) < K/c; not shown here). This is the result of the
memory response being much larger than the effector response, with memory cells also fast approaching
their carrying capacity M . Because of this, in the following we assume that y = ym. In panels (b)-(c) we
compare the choice of parameter c on the tumour growth patterns and observe that, as expected, larger c
leads to lower maximum tumour sizes (see tumour size between days 100-200). The red dashed horizontal
line shows tumour carrying capacity K = 1.8 × 108, and for c = 17000 in panel (c), we observe that
the maximum tumour size is below 107cells/vol, which is the detection level of tumours (corresponding
to a solid tumour diameter of 0.2 cm [28]). Finally, in panels (c)-(d) we compare the effect of ω on the
tumour growth patterns when we fix c (c = 17000), and observe that chaotic dynamics can be lost when
we decrease ω (e.g., to ω = 1.15).
To have a better understanding of the effect of reducing the carrying capacity K on the dynamics
of tumour growth, we show in Figure 7(a) a bifurcation diagram for the local maximum values of xu
versus ω ∈ [1.1, 1.29], as we fix c = 17000. We note that while there is no chaos for ω = 1.15, chaos
still persist for ω ∈ (1.22, 1.27). The inset shows the first-return map to a Poincare´ section of the chaotic
attractor at ω = 1.26. We emphasise this persistence of deterministic chaos by showing in Figure 7(b)
the largest Lyapunov exponent for system (2.1b)-(2.1e) & (4.1) versus ω ∈ (1.22, 1.27), when c = 17000.
To investigate in more detail the effect of c on the persistence or absence of chaotic dynamics, in Figure
7(c),(d) we show bifurcation diagrams for the local maximum values of xu versus c ∈ [0, 17000], when
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Figure 7. Bifurcation diagrams corresponding to tumour dynamics described by equation (4.1). (a)
Bifurcation of local maximum values of xu (for t ∈ [3000, 7000]) versus ω ∈ [1.1, 1.29]. Here c = 17000.
The inset figure shows the first-return map for ω = 1.26. (b) Largest Lyapunov exponent (LE) for
ω ∈ [1.1, 1.29] and c = 17000. (c) Bifurcation of local maximum values of xu (for a fixed ω = 1.26)
versus c ∈ [0, 17000]. The inset figure shows the first-return map for c = 4000. (d) Bifurcation of local
maximum values of xu (for a fixed ω = 1.15) versus c ∈ [0, 17000]. The inset figure shows the first-return
map for c = 5600.
ω = 1.26 and ω = 1.15, respectively. Note that for ω = 1.26 chaos persists for any value of c (panel (c)),
while for ω = 1.15 chaos occurs for c ∈ (5000, 7500) (panel (d)). The persistence of this chaotic behaviour
for ω = 1.26 is likely the result of asymptotic tumour sizes that are much lower than the tumour carrying
capacity K − cM (with M the carrying capacity of ym cells), and thus variations in parameter c do not
have any effect on these tumour sizes.
Finally, to investigate the parameter range where chaotic dynamics can or cannot be detected, we
graph in Figure 8 the local maximum tumour sizes (for time t ∈ (3000, 7000)) as we vary parameter
ω ∈ [1.1, 1.29] and parameter c: (a) c = 0, and (b) c = 17000. Recall that the detection level of tumours
is at least 107 cells, which corresponds to a solid tumour with diameter of 0.2 cm [28]. We first observe
that for c = 17000 the amplitude of the chaotic oscillations is always below 107 cells. However, for c = 0
the maximum amplitude can increase above 107 cells when ω < 1.23 (corresponding to a virus half-life
greater than 13.4hrs). For ω > 1.26 (corresponding to a virus half-life less than 13.2hrs), the amplitude of
the tumour chaotic oscillations is below 104, and thus it is unlikely that such oscillations can be observed
experimentally (due to a lack of sufficiently accurate imaging techniques to measure temporal variations
in tumour size). Overall, this is an unexpected behaviour since the persistence of VSV particles (i.e., low
ω) would suggest that the tumour can be kept under control at smaller sizes.
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Figure 8. Bifurcation dynamics for the maximum size of uninfected tumour cells xu for t ∈
(3000, 7000), as we vary the elimination rate of virus particles ω. The horizontal dotted red line shows
the initial density of tumour cells, xu(0) = 106. The horizontal dashed blue line shows tumour detection
level xu ≈ 107. (a) Initial tumour growth model with c = 0; (b) Modified tumour growth model with
c = 17000. See Tables 1 and 2 for initial conditions and parameter values.
5. Model sensitivity to “free” parameters
Since not all parameter values were known from the literature (see Table 2), in the following we investigate
numerically the dynamics of model (2.1) when we vary the “free” parameters within the ranges shown in
Table 2 (see column “Value”). We emphasise that we vary one parameter at a time, while keeping all other
parameters fixed. Figure 9 shows bifurcation diagrams corresponding to asymptotic (i.e., t ∈ (3000, 7000)
days) changes in tumour size when we vary six estimated parameters: (a) dv, (b) hv, (c) hu, (d) pm, (e)
pe, (f) δ. The estimated values shown in Table 1 (and used throughout this study) are marked in these
panels by a vertical dotted red line. The inset figures show the effect of these parameters on the transient
tumour dynamics (i.e., on tumour size on day t = 50).
We notice in Figure 9(a) that large infection rates dv > 0.03 do not have a significant impact on the
asymptotic behaviour of the tumour (i.e., when t ∈ (3000, 7000) days), but they do reduce the tumour
size on day t = 50 (see the inset figure). Different effects in the transient and asymptotic behaviour of
the tumour can also be observed when varying hv, pm and δ. The free parameters that show consistent
effects on both the transient and asymptotic tumour behaviour are pe (but only for pe > 0.2) and hu (but
only for hu > 3). The increase in pe above pe = 0.2 leads to a decrease in the transient and asymptotic
tumour sizes. On the other hand, the increase in hu above hu = 3 leads to an increase in the transient and
asymptotic tumour sizes. Finally, we note that the asymptotic dynamics of model (2.1) does not seem to
be influenced by parameter pm, the proliferation rate of memory cells; see Figure 9(d). This result is likely
related to the fact that the memory cell population approaches quickly its carrying capacity, and thus
the asymptotic dynamics of the tumour cannot be influenced anymore by variations in these memory cell
numbers.
6. Summary and Discussion
In this article, we introduced a simple, nonlinear mathematical model that described the interactions
among immune cells, cancer cells and viruses following oncolytic immunotherapy. Although this model
was motivated by a specific protocol for cancer virotherapy [10], it could be used to describe other
combinations of cancer immunotherapies, where an initial boost for the immune response is followed by
a secondary boost caused by, for example, virus administration. We emphasise that this mathematical
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Figure 9. Changes in the asymptotic and transient (in the inset) model dynamics, as we vary the free
model parameters: (a) dv , (b) hv , (c) hu, (d) pm, (e) pe, (f) δ. We choose here ω = 1.26. The vertical
red dotted line shows the estimated value (see also Table 2).
model is valid only for tumours that have not yet undergone angiogenesis. In addition, note that our
discussion related to transient regime is very sensitive to initial conditions, and other initial conditions
would have most likely led to different qualitative transient regimes.
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We used this particular mathematical model to investigate the complex asymptotic dynamics of
tumour-virus-immune interactions. First, we assumed a constant tumour carrying capacity and showed
that the tumour will always approach this value (Figure 3). Moreover, we showed that after the tumour
reaches its carrying capacity, the system could exhibit very complex dynamics which included fixed points,
periodic orbits and chaotic behaviour (Figure 4). However, because these dynamics occurred after the
tumour reached its carrying capacity, it was irrelevant from an experimental point of view (since mice
are euthanised once the tumour becomes very large [46]).
To investigate whether complex dynamics can be observed also for smaller tumours, we modified the
model to incorporate the assumption that the carrying capacity depended also on the density of tumour-
infiltrated immune cells. The results showed that the tumour can grow to smaller or larger sizes, depending
on how “tumour hostile” the microenvironment is (Figure 6). Moreover, we showed that the new model
can also exhibit chaotic behaviour - although for slightly different parameter values (Figure 7).
We used bifurcation diagrams to investigate the parameter values for which chaotic dynamics can be
detected in the original system (2.1), i.e., for which the asymptotic tumour size is above the threshold 107
cells (Figure 8). We showed that tumour detection requires a viral clearance rate ω < 1.23 (equivalent to
a virus half-life greater than 13.4hrs). This was completely unexpected since virus persistence is thought
to lead to smaller tumours. For larger ω values (i.e., shorter virus half-life) chaotic dynamics could not
be detected due to the very low amplitudes of oscillations. For these larger ω values the model could
also exhibit periodic cycles, but their very low amplitudes made them undetectable. We note here that
clinical oscillations in the immune response and tumour growth have been previously mentioned in the
literature [16], although such reports are scarce. One possible explanation for the scarcity of these reports
is the current lack of sufficiently accurate imaging techniques capable of measuring temporal variations
in tumour size (to create relevant time series).
We also used bifurcation diagrams to test the sensitivity of our results to changes in the free parameters
(i.e., parameters not identified from the literature; see Figure 9), and showed that some parameters have
opposite effects on the transient (i.e., t = 50) and asymptotic (i.e., t ∈ (3000, 7000)) behaviour of the
tumour size. For example, an increase in hv above 10
4 leads to lower tumour size initially, but to higher
tumour size in the long term. This suggests that anti-cancer treatments that work in the short term by
reducing tumour size and delaying tumour relapse, might not work in the long term. This result may
give insight into why to date oncolytic virotherapies have, on the whole, been unsuccessful [15]. More
precisely, the (nonlinear) interactions between the multiple components of the tumour microenvironment
- immune cells, cancer cells, virus particles - might explain tumour escape in the long term, via the
complex global dynamics that they give rise to (in mathematical terms: multiple unstable steady states,
limit cycles, chaotic dynamics, etc.). However, for a better understanding of the transient and long-term
clinical and experimental observations, one needs to incorporate into the model more detailed dynamics
of the signalling pathways that can be altered during cancer progression.
We would like now to discuss the unexpected behaviour in tumour-virus dynamics we mentioned
previously, namely larger asymptotic tumour sizes (or larger amplitudes of chaotic oscillations) seem to
correspond to longer virus persistence, i.e., smaller ω (see Figure 8). This is in complete contrast with the
transient dynamics, where smaller ω leads to lower tumour sizes and delayed tumour re-growth (see Figure
3). It is unclear at this moment whether this unexpected observation regarding tumour-virus dynamics
is an artefact of the mathematical model, or has been previously observed in the experiments. Many
experimental approaches try to increase the circulating half-life of VSV, with the purpose of decreasing
tumour size [57]. However, if the experimental approaches manage to keep the tumour under control at
almost undetectable sizes, there will be no data comparing the asymptotic dynamics of these very low
tumour sizes.
Throughout this study we focused mostly on the viral clearance rate ω (since it can be manipulated
experimentally [11,31,57]). Due to the complexity of model equations, it is possible that changing other
parameters could lead to different sorts of dynamical transitions. However, because of the very large pa-
rameter space, such an investigation was not the goal of this study. Rather, the goal was to emphasise the
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necessity of investigating the asymptotic dynamics of the mathematical models (investigation performed
here with the help of bifurcation diagrams), to obtain a better understanding of the non-linear effects of
deterministic interactions among the various components of tumour microenvironments and to eventually
generate new questions to be addressed experimentally.
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Appendix A
The following two tables summarise the state variables (Table 1), and describe the parameter values
used throughout this paper (Table 2). The majority of parameter values were obtained from the literature
(see Table 2). There are a few “free” parameters (e.g., pe, pm, hv, hu, dv) for which either we could not find
specific values in the literature, or there were multiple contradictory values. In this case we estimated the
values of these “free” parameters (the sole value in column “Value” in Table 2), and then we investigated
the sensitivity of the model to these parameters for various parameter ranges (the intervals in column
“Value” in Table 2).
State Variables Meaning Initial value
xu Density of uninfected cancer cells 10
6
xi Density of infected cancer cells 0
ym Immune memory cells 5
ye Immune effector cells 35
v Density of oncolytic Vesicular Stomatitis Virus (VSV) particles 103
Table 1. State variables for model (2.1), and the initial values used in simulations.
The initial conditions in Table 1 are based on the experimental results in [10], where 106 B16-F10
tumour cells were injected into C57BL/6 mice. At the time of the injection, the number of CD8+ T cells
detected in blood (following previous priming with Ad+VSV vectors) was less than 250 cells/µl (which
included both effector and memory cells; see Fig. S1 in [10]). Since the immune response following one
viral vector is much lower than the immune response following two viral vectors (see Fig. S2 in [10]), for
this theoretical study we chose ym(0) = 5 and ye(0) = 35. In [10], mice were injected VSV doses of at least
106 pfu. In our study, we investigated the effects of lower initial VSV loads (v(0) = 103). This lower value
incorporates the assumption that only a small fraction of injected VSV particles reaches the tumour (see
Fig. 4 in [10], where VSV brain titres were about 103 − 104 pfu/g, in tumour-free and tumour-bearing
murine brains).
In the following, we discuss some of the assumptions we made about model parameters:
– The B16 melanoma cells proliferate very fast in culture, with a doubling time of 14-19 hours [12].
Throughout this study, we consider a doubling time of about 18 hours, resulting in a proliferation rate
r = 0.927 (see also [27]).
– The death rate δ of cells infected with VSV varies between studies: from δ = 0.69/day in [51] to
δ ∈ (0.665, 6.654)/day in [7]. Throughout this study, we will choose δ = 1.0/day, as in [27,33]. However,
in Section 5, we investigate the model dynamics when δ ∈ (0.665, 6.654)/day.
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Parameter Value Units Description & Reference
r 0.927 days−1 proliferation rate for tumour cells [10,12,27]
K 1/(5.5×10−9) cells/vol carrying capacity for the tumour cells [27]
dv 0.0026
(0.002-0.004)
(cells/vol)(PFU/vol)−1(days)−1 infection rate of tumour cells with the on-
colytic virus
dx 2.6 days
−1 lysis rate of tumour cells (infected and unin-
fected) by the immune cells [36]
hu 1
(10−2-103)
cells/vol half-saturation constant for the tumour cells
infected with the oncolytic virus
he 2× 103 cells/vol half-saturation constant for the effector cells
that support half the maximum killing rate
[67]
hv 10
4
(102-105)
PFU/vol half-saturation constant of viral antigens that
induce half the maximum proliferation rate of
immune cells
δ 1.0
(0.665−6.654)
days−1 rate at which the oncolytic virus kills the tu-
mour cells [7, 27,33]
pm 2.5
(1.25-3.75)
days−1 proliferation rate of memory cells following
secondary encounter with tumour antigens
carried by virus particles
M 104 (cells)/vol carrying capacity for memory cells [4]
pe 0.4
(10−2-1.1)
days−1 rate at which memory cells become effector
cells following secondary encounter with tu-
mour antigens carried by virus particles
de 0.1 days
−1 death rate of effector cells [4, 26]
dt 5× 10−9 (cells)−1(vol)(days)−1 inactivation rate of immune effector cells by
the tumor cells [27]
ω 1.0 − 2.56 days−1 decay rate for the concentration of oncolytic
virus (VSV) particles in the blood [9, 31]
b 1000 (PFU/vol)(cell)−1(vol) number of virus (VSV) particles released from
an infected cell, capable of forming plaques
[27]
Table 2. Parameters of model (2.1) and values used for numerical simulations. Some
of the values were taken from the literature (as referenced). Throughout this article, we
consider the density of cells: cell numbers per blood volume (vol). For mice, the blood
volume is about 1.5-2.5ml. In the “Value” column, the numbers represent the values we
used for the simulations in Sections 3-4, while the intervals represent the ranges used for
the sensitivity analysis in Section 5.
– In [67], the authors showed that between 0.01-10% of CD8 T cells can become functional against
melanoma. In regard to the effector functions of these cells, between 2-44% of them are producing
IFN−γ (i.e., an average of 2% of CD8 T cells in non-lymphoid tissue metastases, an average of 8%
of cells in metastatic lymph nodes, and an average of 44% of cells obtained from peripheral blood
mononuclear cells) [67]. In this study, we assume that an average of 20% of these effector cells contribute
to the half-maximum immune response. Therefore, for a maximum density of effector cell ≈ 104 (as
for the memory cells from which they differentiate), we choose he = 10
4 × 20% = 2× 103 cells.
– The literature is very scarce in information on the level of virus particle necessary to trigger an infection.
In the context of SIV infection in Rhesus macaques, [23] remarked that one viral copy of SIV RNA is
enough for the spread of SIV infection. We could not find any information regarding the number of VSV
particles necessary for the spread of VSV through tumour. Therefore, throughout this study we assume
that the half-saturation constant for tumour cells infected with VSV is hu = 1. Similar assumptions
were made in [27]. However, in Section 5 we investigate model dynamics when hu ∈ (10−2 − 103).
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– The intracellular half-life of nucleocapsids of VSV particles range from 5.3 hours to a maximum of 18
hours for certain virus mutants [21]. The extracellular half-life of VSV particles ranges between 3.5−8
hours at 37◦C [31]. Throughout this work, we assume a virus half-life of tv1/2 ∈ (6.5, 16.5)hours, which
translates into a decay rate ω ∈ (1.0, 2.56)/day. This range is more realistic than the value considered
in [51] of ω = 0.1 (for generalised logistic growth), corresponding to a VSV half life of ≈ 166 hours.
– The mathematical literature shows a wide range of immune cells inactivation rates by the tumour
cells: from dt = 9.42 × 10−12/(cells · day) in [19], to dt = 3.42 × 10−10/(cells · day) in [20] and dt =
2.8× 10−9/(cells · day) in [40]. Here, we use the average value in [27]: dt = 5× 10−9/(cells · day).
Appendix B
Next, we discuss briefly the stability of the steady states of the model. To this end, we show first the
Jacobian associated with system (2.1):
J =

a11 a12 0 a14 a15
a21 a22 0 a24 a25
0 0 a33 0 a35
a41 0 a43 a44 a45
0 a52 0 0 a55
 ,
with
a11 = r
(
1− 2xu + xi
K
)− dvvhu
(hu + xu)2
− dxye
he + ye
, a12 = −rxu
K
,
a14 = − dxxuhe
(he + ye)2
, a15 = − dvxu
hu + xu
, a21 =
dvvhu
(hu + xu)2
,
a22 = −δ − dxye
he + ye
, a24 = − dxxihe
(he + ye)2
, a25 =
dvxu
hu + xu
,
a33 =
pmv
hv + v
(
1− 2ym
M
)
, a35 =
pmymhv
(hv + v)2
(
1− ym
M
)
, a41 = −dtye,
a43 =
pev
hv + v
, a44 = −de − dtxu, a45 = peymhv
(hv + v)2
, a52 = δb,
a55 = −ω.
– The TF state is always unstable (a saddle point), since the the Jacobian matrix always has one positive
eigenvalue: λ1 = r > 0. (The other eigenvalues are λ2 = −δ, λ3 = 0, λ4 = −de, λ5 = −ω.)
– The eigenvalues corresponding to the TO state are λ1 = 0, λ2 = −r, λ3 = −de − dtK and
λ4,5 = −0.5(ω + δ)± 0.5
√
(ω + δ)2 + 4
(
δbdvK/(hu +K)− ωδ
)
.
Hence, the TO state can be stable or unstable, depending the value of Re = bdvK/(ω(hu + K)): if
Re > 1 then λ4 > 0 and the steady state is unstable, while for Re < 1 both λ4,5 < 0 and the steady
state is stable.
– The TV steady state (which exists only when dvb > ω, equivalent to Re > 1) has y
∗
m = 0, which
implies that a35 = 0. Hence, one of the eigenvalues of the Jacobian matrix calculated at the TV state
is λ1 = pmv
∗/(hv + v∗) > 0 and thus this state is always unstable.
– The stability of the TVI state can be investigated only numerically (see the approach in [27]). It can
be shown that this state is unstable for ω < 1.32 (i.e., it is a saddle-focus with three real eigenvalues
λ1,2,3 < 0, and two complex eigenvalues with Re(λ4,5) > 0).
We can summarise these linear stability results in the following result:
Proposition .1. For the parameters described in Table 2, model (2.1) has four different steady states
with the following stability:
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1. The tumour-free equilibrium (TF) is always unstable.
2. The tumour-only equilibrium (TO) is locally asymptotically stable if Re < 1 and unstable if Re > 1
(where Re is given by (3.1)).
3. The tumour-with-virus (and no immune) equilibrium (TV) is always unstable.
4. The coexistence equilibrium (TVI), where all cells and viral particles are nonzero, is locally asymptotical
stable if ω ≥ 1.32 and unstable if ω < 1.32 (and all other parameters fixed as in Table 2).
Appendix C
To obtain a better understanding of how the chaotic attractors are structured around the fixed points
of system (2.1), we show in Figure 10 one such attractor in the xu−ye plane, together with all fixed points
corresponding to ω = 1.26 (and all other parameters as in Table 2). For these particular parameters, the
values of the fixed points of system (2.1) are as follows:
– TF: (xu, xi, ym, ye, v) = (0, 0, 10
4, 0, 0);
– TO: (xu, xi, ym, ye, v) = (1.81818181× 108, 0, 104, 0, 0);
– TV: (xu, xi, ym, ye, v) = (0.94, 0.8716, 0, 0, 691.791);
– TVI: (xu, xi, ym, ye, v) = (9.2693, 0.32, 10
4, 992.8991, 254.5433).
We note that the chaotic attractor forms around the unstable TVI steady state.
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Figure 10. Chaotic attractor (in the xu − ye plane) exhibited by model (2.1), when
ω = 1.26 (and all other parameters as in Table 2). In addition, we show the fixed points
TF, TO, TV and TVI (corresponding to these parameter values).
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